Pro-Pharmaceuticals, Inc.
Records under this name other than the patents Pro-Pharmaceuticals, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 2 patents it holds.
Showing 1 to 10 of 10 · Back to Pro-Pharmaceuticals, Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,744,154 | Galactose-pronged polysaccharides in a formulation for antifibrotic therapies Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 8,236,780 | Galactose—pronged polysaccharides in a formulation for antifibrotic therapies Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 9,200,090 | Galactose-pronged polysaccharides in a formulation for antifibrotic therapies Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 7,491,708 | Modified pectin Formerly held Term ended Term ended Feb 17, 2026 · From the USPTO record | Term ended | Term ended Feb 17, 2026 | From the USPTO record |
| US 7,893,252 | Selectively depolymerized galactomannan polysaccharide Formerly held Term ended Term ended Sep 8, 2023 · From the USPTO record | Term ended | Term ended Sep 8, 2023 | From the USPTO record |
| US 7,012,068 | Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer Formerly held Term ended Term ended Dec 22, 2022 · From the USPTO record | Term ended | Term ended Dec 22, 2022 | From the USPTO record |
| US 6,642,205 | Methods and compositions for reducing side effects in chemotherapeutic treatments Formerly held Term ended Term ended Sep 24, 2021 · From the USPTO record | Term ended | Term ended Sep 24, 2021 | From the USPTO record |
| US 6,982,255 | Delivery of a therapeutic agent in a formulation for reduced toxicity Formerly held Term ended Term ended Jul 19, 2021 · From the USPTO record | Term ended | Term ended Jul 19, 2021 | From the USPTO record |
| US 6,645,946 | Delivery of a therapeutic agent in a formulation for reduced toxicity Formerly held Term ended Term ended May 21, 2021 · From the USPTO record | Term ended | Term ended May 21, 2021 | From the USPTO record |
| US 6,914,055 | Delivery of a therapeutic agent in a formulation for reduced toxicity Formerly held Term ended Ended no later than Mar 27, 2021 · From the USPTO record | Term ended | Ended no later than Mar 27, 2021 | From the USPTO record |